Sleep Apnea Raises Gout Risk
Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.
News
New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis
The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.
RheumNow Week in Review – Father Knows Best (Paternal Drugs OK) (8.31.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Cool info on paternal exposures to DMARDs/Biologics, Contraceptive let downs, good outcomes in PsA, depression-insomnia-pain triad in OA and how to store your biologic in a hurricane.
No Cancer Risk from Psoriatic Arthritis
Inflammmation is a strong risk factor for malignancy. Yet there are mixed results on whether patients with psoriatic arthritis (PsAg) augments the incidence of cancer and all-cause and cause-mortality.
Treatment Preferences in Still’s Disease
In July 2018, RheumNow launched a “Live Vote” survey of US and non-US rheumatologists that asked how they diagnose and treat systemic juvenile idiopathic arthritis (sJIA), also known as “Still’s disease”. It appears that many prefer to start therapy with an IL-1 inhibitor, after a course of steroids and MTX/DMARD. Yet, these findings suggest there are significant unmet needs in the diagnosis and management of sJIA patients.
2018 EULAR Recommendations for Hand Osteoarthritis Care
The European League Against Rheumatism (EULAR) has previously put forth recommendations for management of hand osteoarthritis (OA) in 2007. But since then, advances and further evidence have emerged.
Adherence to Gout Therapies Painfully Low
A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.
The Safety of Paternal Exposure to DMARDs and Biologics
Pregnancy and drug safety is a complex issue, often with limited informatoin about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.
Questions Remain about Shingrix Safety in Rheumatic Disease
The efficacy and safety of the new zoster vaccine Shingrix has not been established among patients with autoimmune diseases, researchers reported here.
2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination
The current issue of the CDC's MMWR reviews the new seasonal recommendations for vaccination against influenza. This is an update to the previous recommendations of the Advisory Committee on Immunization Practices (ACIP).
Not All Hyperuricemia Leads to Gout
Dalbeth and colleagues studied 4 large prospective cohorts and found that rising levels of serum uric acid (SUA) leads to a non-linear increased risk of incident gout, but only half of those with SUA ≥10mg/dL developed clinically evident gout.
RheumNow Week in Review – How Not to Treat Hand OA (8.24.18)
Dr. Jack Cush comments on the last week's news and journal highlights on RheumNow.com.
Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis
A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious, hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.
Outcomes of Systemic Sclerosis Hospitalization
A study of inpatient systemic sclerosis (SSc) hospitalizations using the 2012–13 National Inpatient Sample database finds an inpatient mortality rate of 5%, and that infection was the most common cause of SSc hospitalizations and in-hospital death.
IL-12 and IL-23 Promote Giant Cell Arteritis
It has been postulated that TH1 and TH17 pathways are implicated in the pathogenesis of giant cell arteritis (GCA); this is supported by new research showing that interleukin 12 (IL-12) and interleukin 23 (IL-23) may stimulate inflammatory and proliferative pathways relevant to the path
